Literature DB >> 12547603

Immunostimulating reconstituted influenza virosomes.

Rinaldo Zurbriggen1.   

Abstract

Immunostimulating reconstituted influenza virosomes (IRIVs) are a liposomal carrier system. Influenza hemagglutinin and neuraminidase are intercalated into the lipid bilayer and give the IRIVs their fusogenic activity. The system is already registered for human use and allows a specific targetting of antigens to a cellular or a humoral immune response. IRIVs are able to deliver proteins, RNA/DNA, peptides and mimetics to immunocompetent cells.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12547603     DOI： 10.1016/s0264-410x(02)00541-8

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

Review 2.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

3.  Surfactant assemblies and their various possible roles for the origin(s) of life.

Authors:  Peter Walde
Journal:  Orig Life Evol Biosph       Date:  2006-04-27       Impact factor: 1.950

Review 4.  Peptides for Vaccine Development.

Authors:  Ian W Hamley
Journal:  ACS Appl Bio Mater       Date:  2022-02-23

Review 5.  Nanoparticle delivery systems in cancer vaccines.

Authors:  Yogita Krishnamachari; Sean M Geary; Caitlin D Lemke; Aliasger K Salem
Journal:  Pharm Res       Date:  2010-08-19       Impact factor: 4.580

6.  Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.

Authors:  Patrick Georges Cech; Thomas Aebi; Mwanajaa Shomari Abdallah; Maxmillian Mpina; Ester Barnabas Machunda; Nicole Westerfeld; Sabine Alexandra Stoffel; Rinaldo Zurbriggen; Gerd Pluschke; Marcel Tanner; Claudia Daubenberger; Blaise Genton; Salim Abdulla
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

Review 7.  Adjuvants: Classification, Modus Operandi, and Licensing.

Authors:  Juliana de Souza Apostólico; Victória Alves Santos Lunardelli; Fernanda Caroline Coirada; Silvia Beatriz Boscardin; Daniela Santoro Rosa
Journal:  J Immunol Res       Date:  2016-05-04       Impact factor: 4.818

8.  A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.

Authors:  Blaise Genton; Gerd Pluschke; Lukas Degen; Andreas R Kammer; Nicole Westerfeld; Shinji L Okitsu; Sandro Schroller; Penelope Vounatsou; Markus M Mueller; Marcel Tanner; Rinaldo Zurbriggen
Journal:  PLoS One       Date:  2007-10-10       Impact factor: 3.240

9.  A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial.

Authors:  Shinji L Okitsu; Olivier Silvie; Nicole Westerfeld; Marija Curcic; Andreas R Kammer; Markus S Mueller; Robert W Sauerwein; John A Robinson; Blaise Genton; Dominique Mazier; Rinaldo Zurbriggen; Gerd Pluschke
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

Review 10.  Virosome presents multimodel cancer therapy without viral replication.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Biomed Res Int       Date:  2013-12-04       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.